|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
CN1933847A
(zh)
*
|
2004-01-16 |
2007-03-21 |
密歇根大学董事会 |
Smac肽模拟物及其应用
|
|
US7932382B2
(en)
*
|
2004-01-16 |
2011-04-26 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
EP2253614B1
(en)
|
2004-04-07 |
2012-09-19 |
Novartis AG |
Inhibitors of IAP
|
|
MXPA06014969A
(es)
*
|
2004-07-02 |
2007-02-08 |
Genentech Inc |
Inhibidores de iap.
|
|
WO2006010118A2
(en)
*
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
CA2573644A1
(en)
*
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
|
EP1773766B1
(en)
|
2004-07-15 |
2014-04-02 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
|
ATE477254T1
(de)
|
2004-12-20 |
2010-08-15 |
Genentech Inc |
Pyrrolidine als inhibitoren von iap
|
|
BRPI0607988A2
(pt)
|
2005-02-25 |
2009-10-27 |
Tetralogic Pharmaceuticals |
composto, composição farmacêutica, e método para induzir apoptose em uma célula
|
|
US7772177B2
(en)
|
2005-05-18 |
2010-08-10 |
Aegera Therapeutics, Inc. |
BIR domain binding compounds
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20070042428A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Stacy Springs |
Treatment of proliferative disorders
|
|
JP2009512719A
(ja)
*
|
2005-10-25 |
2009-03-26 |
アエゲラ セラピューティクス インコーポレイテッド |
Ｉａｐｂｉｒドメイン結合化合物
|
|
CN101374829A
(zh)
*
|
2005-12-19 |
2009-02-25 |
健泰科生物技术公司 |
Iap的抑制剂
|
|
TWI543988B
(zh)
|
2006-03-16 |
2016-08-01 |
科學製藥股份有限公司 |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
AU2007250443B2
(en)
*
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
WO2008014236A1
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100144650A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014252A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
AR063943A1
(es)
|
2006-07-24 |
2009-03-04 |
Tetralogic Pharmaceuticals Cor |
Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110224A1
(es)
|
2006-08-02 |
2011-04-05 |
Novartis Ag |
PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
|
|
JP2010501567A
(ja)
*
|
2006-08-24 |
2010-01-21 |
ノバルティス アクチエンゲゼルシャフト |
代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物
|
|
BRPI0718509A2
(pt)
*
|
2006-09-22 |
2015-09-29 |
Novartis Ag |
compostos orgânicos heterocíclicos
|
|
RU2009117701A
(ru)
*
|
2006-10-12 |
2010-11-20 |
Новартис АГ (CH) |
Производные пирролидина в качестве ингибиторов iap
|
|
JP2010513561A
(ja)
*
|
2006-12-19 |
2010-04-30 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのイミダゾピリジンインヒビター
|
|
CA2672776A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Novartis Ag |
2-substituted 5-membered heterocycles as scd inhibitors
|
|
AU2008240153B2
(en)
*
|
2007-04-12 |
2013-01-31 |
Joyant Pharmaceuticals, Inc. |
SMAC mimetic dimers and trimers useful as anti-cancer agents
|
|
CN101687787A
(zh)
|
2007-04-30 |
2010-03-31 |
健泰科生物技术公司 |
Iap的抑制剂
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
|
|
US20100203012A1
(en)
*
|
2007-05-30 |
2010-08-12 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
|
KR20100110870A
(ko)
*
|
2008-01-11 |
2010-10-13 |
제넨테크, 인크. |
Ｉａｐ의 억제제
|
|
WO2009136290A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
AU2009261919A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Pharmascience Inc. |
Bridged secondary amines and use thereof as IAP BIR domain binding compounds
|
|
NZ590550A
(en)
*
|
2008-08-02 |
2013-05-31 |
Genentech Inc |
Inhibitors of Apoptosis (IAP) for treating cancer
|
|
US20110218211A1
(en)
*
|
2008-08-16 |
2011-09-08 |
Genentech, Inc. |
Azaindole inhibitors of iap
|
|
CA2736505A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
Iap inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
US20120196793A1
(en)
|
2009-09-18 |
2012-08-02 |
Firestone Brant G |
Biomarkers for iap inhibitor compounds
|
|
WO2011059763A2
(en)
|
2009-10-28 |
2011-05-19 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
EP2534170B1
(en)
*
|
2010-02-12 |
2017-04-19 |
Pharmascience Inc. |
Iap bir domain binding compounds
|
|
CN103119034B
(zh)
|
2010-04-16 |
2016-08-03 |
拜耳知识产权有限责任公司 |
作为害虫防治剂的杂环化合物
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
EP2760446A1
(en)
|
2011-09-30 |
2014-08-06 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
SG11201406837TA
(en)
|
2012-05-04 |
2014-11-27 |
Novartis Ag |
Biomarkers for iap inhibitor therapy
|
|
JP6382831B2
(ja)
|
2012-11-30 |
2018-08-29 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
BR112015021134A2
(pt)
|
2013-03-15 |
2017-10-10 |
Novartis Ag |
conjugados de fármaco e anticorpo
|
|
KR20200108904A
(ko)
|
2013-06-25 |
2020-09-21 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
LT3083616T
(lt)
|
2013-12-20 |
2021-09-10 |
Astex Therapeutics Limited |
Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje
|
|
CA2974651A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9811383B2
(en)
*
|
2014-05-05 |
2017-11-07 |
Empire Technology Development Llc |
Processing a composite task based on a semantic relation graph
|
|
US10300074B2
(en)
|
2014-06-04 |
2019-05-28 |
Sanford Burnham Prebys Medical Discovery Institute |
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
TN2016000577A1
(en)
|
2014-08-12 |
2018-04-04 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
GB201414730D0
(en)
*
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
HK1247204A1
(zh)
|
2015-01-20 |
2018-09-21 |
Arvinas Operations, Inc. |
用於雄激素受体的靶向降解的化合物和方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
|
UA124672C2
(uk)
|
2016-06-21 |
2021-10-27 |
Оріон Офтальмолоджі Ллс |
Гетероциклічні похідні пролінаміду
|
|
JP7286539B2
(ja)
|
2016-11-01 |
2023-06-05 |
アルビナス・オペレーションズ・インコーポレイテッド |
タウタンパク質標的化ｐｒｏｔａｃ、および関連使用方法
|
|
DK3689868T3
(da)
|
2016-12-01 |
2024-01-02 |
Arvinas Operations Inc |
Tetrahydronaphthalen- og tetrahydroisoquinolinderivater som østrogenreceptordegraderende midler
|
|
AU2017382436C1
(en)
|
2016-12-23 |
2021-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
EP3573977A4
(en)
|
2017-01-26 |
2020-12-23 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
|
JP2020520665A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
|
WO2019091492A1
(zh)
*
|
2017-11-13 |
2019-05-16 |
南京明德新药研发股份有限公司 |
用作iap抑制剂的smac模拟物及其用途
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
CN119569702A
(zh)
|
2018-04-04 |
2025-03-07 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
RS64759B1
(sr)
|
2018-07-10 |
2023-11-30 |
Novartis Ag |
3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-dion derivati i njihova primena u lečenju bolesti zavisnih od cink prsta 2 (ikzf2) iz porodice ikaros
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020041331A1
(en)
|
2018-08-20 |
2020-02-27 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
KR102642203B1
(ko)
|
2018-09-07 |
2024-03-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
SG11202106629PA
(en)
|
2018-12-21 |
2021-07-29 |
Novartis Ag |
Antibodies to pmel17 and conjugates thereof
|
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
BR112021015783A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
|
|
AU2020233068B2
(en)
*
|
2019-03-07 |
2025-04-24 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Combination of IAP inhibitor and immune checkpoint inhibitor
|
|
EP3967702B1
(en)
*
|
2019-05-10 |
2024-03-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystallization of smac mimic used as iap inhibitor and preparation method thereof
|
|
US11912699B2
(en)
|
2019-07-17 |
2024-02-27 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated
|
|
EP4007592A1
(en)
|
2019-08-02 |
2022-06-08 |
LanthioPep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
AU2020406350A1
(en)
|
2019-12-20 |
2022-08-11 |
Novartis Ag |
Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
WO2021148396A1
(en)
|
2020-01-20 |
2021-07-29 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
JP2023539663A
(ja)
|
2020-08-28 |
2023-09-15 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
CN116390916A
(zh)
|
2020-09-14 |
2023-07-04 |
阿尔维纳斯运营股份有限公司 |
用于靶向降解雌激素受体的化合物的结晶形式
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
MX2023012277A
(es)
|
2021-04-16 |
2023-12-07 |
Novartis Ag |
Conjugados anticuerpo-fármaco y métodos para fabricar los mismos.
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
US20250353847A1
(en)
|
2022-07-26 |
2025-11-20 |
Novartis Ag |
Crystalline forms of an akric3 dependent kars inhibitor
|
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
|
WO2024159164A2
(en)
|
2023-01-26 |
2024-08-02 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|